Latest Breaking News On - Mina pastagia - Page 1 : vimarsana.com

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a diSArm Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a diSArm Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJoyce allaireMina pastagiaPierre kymeDeborah birxDefense health agencyNaval medical researchData review committeeDepartment of defenseArmata pharmaceuticals incLifesci advisorsUs department of defenseTechnology enterprise consortiumWarfighter medical research programPrnewswire armata pharmaceuticals incChief executive officer

Targeting Phage Therapy World Conference 2023

The 6th World Conference on Targeting Phage Therapy 2023 which will be held in Paris on June 1-2 will welcome more than 70 communications (major, short and poster presentations), and gather more than 150 international in-person and virtual participants from 31 countries.

Baylor college of medicineUnited statesUnited kingdomTexas medical centerSouth koreaCzech republicFrance generalRepublic of koreaMartha clokieAmanda burkardtMarvin edeasAnthony maressoMina pastagiaIddo nadav weinerAdam ostrowskiOptipharm inc

Phage cocktail, AP-PA02, may safely treat Pseudomonas aeruginosa infection | Early CF trial reports safety, potential efficacy

The phage therapy was well tolerated and eased Pseudomonas aeruginosa airway load in treated trial patients, Phase 2b CF study proposed.

Brian varnumMina pastagiaArmata pharmaceuticals

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P a Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

/PRNewswire/ Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific.

United statesMina pastagiaBrian varnumJoyce allairePierre kymeLifesci advisorsArmata pharmaceuticals incPrnewswire armata pharmaceuticals incNon cystic fibrosis bronchiectasisChief medical officerChief executive officerArmata pharmaceuticalsAnnual reportSci advisors

Armata Pharmaceuticals to Present at the 2021 World Antimicrobial Resistance Congress

/PRNewswire/ Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted.

United statesMina pastagiaJoyce allairePierre kymeLifesci advisorsArmata pharmaceuticals incWorld antimicrobial resistance congressClinical developmentArmata pharmaceuticalsVice presidentAntimicrobial resistance congressInnovation showcaseGrand hyatt washingtonInvestor relationsSci advisors